文献速递免疫规划传染病防控与疫情报告

重组带状疱疹疫苗上市后初始安全性监测综述

Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
PubMed 文献 · Vaccine · 2019-12-07

该综述总结了2017年10月13日至2019年2月10日期间GSK通过自发不良事件报告系统收到的重组带状疱疹疫苗(RZV)安全性数据。观察值与预期值分析及数据挖掘未发现非预期模式,RZV安全性特征与上市前临床试验一致。

要点

  • 报告症状与临床试验已知反应原性特征一致,包括注射部位反应、发热、寒战、疲劳、头痛。
  • 观察值与预期值分析及数据挖掘未发现非预期模式,RZV安全性特征与上市前临床试验一致。

核心结论

  • 上市后安全性监测初始数据综述显示,RZV的安全性特征与上市前临床试验中观察到的一致。
  • 其他研究正在进行和计划中,以持续生成真实世界安全性数据并进一步表征RZV。

研究设计与样本

  • 总结2017年10月13日至2019年2月10日期间GSK通过自发不良事件报告系统收到的RZV接种后安全性信息,报告来自医疗保健提供者、疫苗接种者及其他报告者。
  • 对选定结局(死亡、吉兰-巴雷综合征、贝尔麻痹)进行观察值与预期值(O/E)分析,并使用标准病例定义评估个体病例报告。
  • 采用比例报告比和发病时间信号检测方法进行数据挖掘,以识别报告比例失衡或发病时间分布非预期的RZV-不良事件配对。

主要发现

  • 大多数报告 classified 为非严重性(95.3%),来源于美国(81.7%),美国分发了多数疫苗剂量。
  • 在有年龄或性别报告的报告者中,主要为50-69岁个体(62.1%)和女性(66.7%)。
  • 所有报告中3579份(22.9%)描述接种错误,其中82.7%无相关症状;接种错误报告中多数描述疫苗准备和复溶错误(29.7%)、不适当接种程序或不完整接种疗程(26.7%)、接种途径错误(16.4%)和储存错误(12.9%)。
  • 最常报告的症状与临床试验中观察到的已知RZV反应原性特征一致,包括注射部位反应、发热、寒战、疲劳、头痛。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) received its first marketing authorization in October 2017, for prevention of herpes zoster in individuals aged ≥50 years. METHODS: We summarized safety information, following RZV administration, received by GSK via spontaneous adverse event (AE) reports submitted by healthcare providers, vaccine recipients and other reporters. Observed-to-expected (O/E) analyses were performed for selected outcomes: reports of death, Guillain-Barré syndrome and Bell's palsy. Standard case definitions were used to assess individual case reports. Data mining, using proportional reporting ratio and time-to-onset signal detection methods, was employed to identify RZV-AE pairs with disproportionate reporting or unexpected time-to-onset distribution. RESULTS: Between October 13, 2017 and February 10, 2019, an estimated 9.3 million doses were distributed and GSK received 15,638 spontaneous AE reports involving RZV. Most reports were classified as non-serious (95.3%) and originated from the United States (81.7%), where the majority of doses were distributed. Among reports with age or sex reported, individuals were mainly 50-69-year-olds (62.1%) and female (66.7%). Of all reports, 3,579 (22.9%) described vaccination errors, of which 82.7% were without associated symptoms. Of all vaccination error reports, most described errors of vaccine preparation and reconstitution (29.7%), inappropriate schedule or incomplete course of administration (26.7%), incorrect route of administration (16.4%), and storage errors (12.9%). The most commonly reported symptoms were consistent with the known RZV reactogenicity profile observed in clinical trials, including injection site reactions, pyrexia, chills, fatigue, headache. O/E analyses for selected outcomes and data mining analyses for all reported AEs did not identify any unexpected patterns. CONCLUSIONS: Review of the initial data from the post-marketing safety surveillance showed that the safety profile of RZV is consistent with that previously observed in pre-licensure clinical trials. Other studies are ongoing and planned, to continue generating real-world safety data and further characterize RZV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tavares-Da-Silva F, Co MM, Dessart C, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine. 2019. PMID: 31818534. doi:10.1016/j.vaccine.2019.11.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。